LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) reported 2025 results with revenues of ...

The company said that the acquisition adds Faeth’s lead investigational therapy, PIKTOR, to its oncology portfolio.

Acquisition of Faeth and concurrent $200 million private investment positions the combined company to advance its pipeline across key clinical milestones in endometrial and breast cancerPIKTOR is an ...

Investing.com -- Sensei Biotherapeutics (NASDAQ:SNSE) stock soared 200% Wednesday after the company announced its acquisition of Faeth Therapeutics and a concurrent $200 million private placement.

Sensei Biotherapeutics is undertaking a significant operational realignment. This strategic pivot is fueled by a substantial private placement that raised approximately $200 million and the promotion ...

This work investigates ZC3H11A as a cause of high myopia through the analysis of human data and experiments with genetic knockout of Zc3h11a in mouse, providing a useful model of myopia. The evidence ...

The PI3K/AKT/mTOR signaling pathway plays a critical role in regulating cellular growth, survival, metabolism, and proliferation. In prostate cancer, especially in advanced stages, this pathway ...

Antioxidant-1 may promote HCC carcinogenesis through the activation of the c-Myb/PI3K/AKT pathway and the inhibition of copper accumulation and oxidative stress. Despite advancements in diagnostic and ...